Saikosaponin B2CAS# 58316-41-9 |
- Saikosaponin B1
Catalog No.:BCN5917
CAS No.:58558-08-0
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 58316-41-9 | SDF | Download SDF |
| PubChem ID | 21637642 | Appearance | White powder |
| Formula | C42H68O13 | M.Wt | 780.98 |
| Type of Compound | Triterpenoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in methanol; slightly soluble in water | ||
| Chemical Name | (2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-2-[[(3S,4R,4aR,6aR,6bS,8R,8aS,14aR,14bS)-8-hydroxy-4,8a-bis(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,14a-dodecahydropicen-3-yl]oxy]-3,5-dihydroxy-6-methyloxan-4-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol | ||
| SMILES | CC1C(C(C(C(O1)OC2CCC3(C(C2(C)CO)CCC4(C3C=CC5=C6CC(CCC6(C(CC54C)O)CO)(C)C)C)C)O)OC7C(C(C(C(O7)CO)O)O)O)O | ||
| Standard InChIKey | WRYJYFCCMSVEPQ-ORAXXRKOSA-N | ||
| Standard InChI | InChI=1S/C42H68O13/c1-21-29(47)34(55-35-32(50)31(49)30(48)24(18-43)53-35)33(51)36(52-21)54-28-11-12-38(4)25(39(28,5)19-44)10-13-40(6)26(38)9-8-22-23-16-37(2,3)14-15-42(23,20-45)27(46)17-41(22,40)7/h8-9,21,24-36,43-51H,10-20H2,1-7H3/t21-,24-,25-,26-,27-,28+,29+,30-,31+,32-,33-,34+,35+,36+,38+,39+,40-,41-,42-/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Saikosaponin B2 as an efficient inhibitor of early HCV entry, including neutralization of virus particles, preventing viral attachment, and inhibiting viral entry/fusion. It (5 microM) induces differentiation of B16 melanoma cells, with potentiation of expressions of melanogenesis and tyrosinase. |
| Targets | HCV | PKC |
| In vitro | Saikosaponin b2 is a naturally occurring terpenoid that efficiently inhibits hepatitis C virus entry.[Pubmed: 25450204]J Hepatol. 2015 Mar;62(3):541-8.A vaccine against hepatitis C virus (HCV) is unavailable and cost-effective antivirals that prevent HCV infection and re-infection, such as in the transplant setting, do not exist. In a search for novel and economical prophylactic agents, we examined the antiviral activity of saikosaponins (SSa, SSb2, SSc, and SSd) from Bupleurum kaoi root (BK) as entry inhibitors against HCV infection.
|
| Cell Research | Saikosaponin b2-induced apoptosis of cultured B16 melanoma cell line through down-regulation of PKC activity.[Pubmed: 8605013]Biochem Biophys Res Commun. 1996 Feb 15;219(2):480-5.Saikosaponin B2 (SSb2)was found to inhibit the proliferation of B16 melanoma cells.
|
Saikosaponin B2 Dilution Calculator
Saikosaponin B2 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.2804 mL | 6.4022 mL | 12.8044 mL | 25.6089 mL | 32.0111 mL |
| 5 mM | 0.2561 mL | 1.2804 mL | 2.5609 mL | 5.1218 mL | 6.4022 mL |
| 10 mM | 0.128 mL | 0.6402 mL | 1.2804 mL | 2.5609 mL | 3.2011 mL |
| 50 mM | 0.0256 mL | 0.128 mL | 0.2561 mL | 0.5122 mL | 0.6402 mL |
| 100 mM | 0.0128 mL | 0.064 mL | 0.128 mL | 0.2561 mL | 0.3201 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Kusunokinin
Catalog No.:BCN3226
CAS No.:58311-20-9
- Nanaomycin C
Catalog No.:BCC4016
CAS No.:58286-55-8
- Kakkalide
Catalog No.:BCN8263
CAS No.:58274-56-9
- ICA 069673
Catalog No.:BCC7911
CAS No.:582323-16-8
- BMS265246
Catalog No.:BCC3741
CAS No.:582315-72-8
- Betulin palmitate
Catalog No.:BCN5792
CAS No.:582315-55-7
- Tetraethyl ranelate
Catalog No.:BCC9177
CAS No.:58194-26-6
- H-DL-Ser-OMe.HCl
Catalog No.:BCC3100
CAS No.:5819-04-5
- Idebenone
Catalog No.:BCC4913
CAS No.:58186-27-9
- Ethyl 5-amino-4-cyano-3-(2-ethoxy-2-oxoethyl)thiophene-2-carboxylate
Catalog No.:BCC8975
CAS No.:58168-20-0
- Militarine
Catalog No.:BCN2551
CAS No.:58139-23-4
- NSC 207895 (XI-006)
Catalog No.:BCC2243
CAS No.:58131-57-0
- Saikosaponin B3
Catalog No.:BCN8178
CAS No.:58316-42-0
- 4,4'-Bis(N-carbazolyl)-1,1'-biphenyl
Catalog No.:BCC8660
CAS No.:58328-31-7
- Isopimaric acid
Catalog No.:BCN4618
CAS No.:5835-26-7
- DL-Demethylcoclaurine
Catalog No.:BCC8317
CAS No.:5843-65-2
- Dihydroresveratrol
Catalog No.:BCN5793
CAS No.:58436-28-5
- H-2-Nal-OH.HCl
Catalog No.:BCC3287
CAS No.:58438-03-2
- Boc-2-Nal-OH
Catalog No.:BCC3289
CAS No.:58438-04-3
- Angiotensin 1/2 (1-5)
Catalog No.:BCC1035
CAS No.:58442-64-1
- H-D-Leu-OMe.HCl
Catalog No.:BCC2681
CAS No.:5845-53-4
- N-(2-Hydroxy-4-methoxyphenyl)acetamide
Catalog No.:BCN1409
CAS No.:58469-06-0
- Darlingine
Catalog No.:BCN1906
CAS No.:58471-10-6
- Ferrugine
Catalog No.:BCN1910
CAS No.:58471-11-7
Saikosaponin b2-induced apoptosis of cultured B16 melanoma cell line through down-regulation of PKC activity.[Pubmed:8605013]
Biochem Biophys Res Commun. 1996 Feb 15;219(2):480-5.
Saikosaponin (SS) b2 was found to inhibit the proliferation of B16 melanoma cells. To explore this mechanism, we employed flow cytometry to determine the distribution of DNA content. The cell cycle of B16 melanoma cells was accumulated in the G1 phase followed by induction of apoptosis. This suggests that SSb2-induced proliferation inhibition is caused by G1 phase accumulation and that apoptosis induction is G1-phase-accumulation dependent. Phorbol 12-myristate 13-acetate (PMA), a protein kinase C (PKC) activator, did not interfere with the proliferation and did not induce apoptosis of B16 melanoma cells by itself. However, PMA significantly abolished these effects of SSb2 in including proliferation inhibition and apoptosis induction. Down-regulation of the PKC activity may be involved in the effect of SSb2.
Saikosaponin b2 induces differentiation without growth inhibition in cultured B16 melanoma cells.[Pubmed:9872567]
Cell Struct Funct. 1998 Oct;23(5):265-72.
Treatment with 5 microM of saikosaponin (SS) b2 for 30 days was found to induce differentiation of B16 melanoma cells, with potentiation of expressions of melanogenesis and tyrosinase. To explore the mechanism of this effect, we observed the cell growth, cell cycle and morphology, and found that SSb2 did not affect any of these parameters. That is, SSb2 induced the differentiation of B16 melanoma cells without growth inhibition or cytotoxicity under conditions of low dose and long-term treatment. Phorbol ester, a protein kinase C (PKC) activator, markedly inhibited the expressions of melanogenesis and tyrosinase in both the control B16 melanoma cells and the long-term treated B16 melanoma cells. Down-regulation of the PKC activity may be involved in the effects of SSb2.
Saikosaponin b2 is a naturally occurring terpenoid that efficiently inhibits hepatitis C virus entry.[Pubmed:25450204]
J Hepatol. 2015 Mar;62(3):541-8.
BACKGROUND & AIMS: A vaccine against hepatitis C virus (HCV) is unavailable and cost-effective antivirals that prevent HCV infection and re-infection, such as in the transplant setting, do not exist. In a search for novel and economical prophylactic agents, we examined the antiviral activity of saikosaponins (SSa, SSb2, SSc, and SSd) from Bupleurum kaoi root (BK) as entry inhibitors against HCV infection. METHODS: Infectious HCV culture systems were used to examine the effect of saikosaponins on the complete virus life cycle (entry, RNA replication/translation, and particle production). Antiviral activity against various HCV genotypes, clinical isolates, and infection of primary human hepatocytes were also evaluated. RESULTS: BK and the saikosaponins potently inhibited HCV infection at non-cytotoxic concentrations. These natural agents targeted early steps of the viral life cycle, while leaving replication/translation, egress, and spread relatively unaffected. In particular, we identified SSb2 as an efficient inhibitor of early HCV entry, including neutralization of virus particles, preventing viral attachment, and inhibiting viral entry/fusion. Binding analysis, using soluble viral glycoproteins, demonstrated that SSb2 acted on HCV E2. Moreover, SSb2 inhibited infection by several genotypic strains and prevented binding of serum-derived HCV onto hepatoma cells. Finally, treatment with the compound blocked HCV infection of primary human hepatocytes. CONCLUSIONS: Due to its potency, SSb2 may be of value for development as an antagonist of HCV entry and could be explored as prophylactic treatment during the course of liver transplantation.
